Alle Studien
AutorisiertTherapeutische Bestätigung (Phase III)Interventionell

C0371017 - A PHASE 3, NON-INVESTIGATIONAL PRODUCT, MULTI COUNTRY COHORT STUDY TO DESCRIBE THE LONG-TERM SAFETY AND EFFECTIVENESS OF A PRIOR SINGLE-DOSE TREATMENT WITH INVESTIGATIVE GIROCTOCOGENE FITELPARVOVEC OR FIDANACOGENE ELAPARVOVEC IN PARTICIPANTS WITH HEMOPHILIA A OR HEMOPHILIA B, RESPECTIVELY

This study is called C0371017 and it's all about understanding the long-term effects of special gene therapies for haemophilia A and haemophilia B. These therapies involve a single treatment, and scientists want to follow people who have received them for a long time. The main goal is to check how safe these treatments are and how well they continue to prevent bleeding. Researchers will look for things like blood clots, liver issues, and if the treatment causes the body to react against it. They also want to see if people need less of their usual haemophilia medicine after the gene therapy. This study is for adult males and aims to give doctors and patients a clearer picture of these new treatments.

Auf einen Blick

Status
Autorisiert
Phase
Therapeutische Bestätigung (Phase III)
Sponsor
Pfizer Inc.
Einschreibeziel
31
Starten
20. Apr 2026

Worum geht es in dieser Studie?

This study, known as C0371017, is designed to keep a close eye on people who have already received a single gene therapy treatment for haemophilia A or haemophilia B. Think of it as a long-term follow-up to understand how these new treatments work over many years. Haemophilia is a condition where your blood doesn't clot properly, leading to bleeding problems. Gene therapy aims to give your body the instructions it needs to make the clotting factors it's missing.

Researchers want to understand two main things: how safe these gene therapies are in the long run, and how well they continue to help people. Safety is very important, so they will be looking out for any unexpected side effects, such as blood clots, liver problems, or if the body develops a reaction to the treatment. They will also check if the treatment continues to help you make enough clotting factor to prevent bleeds.

Why does this matter? New treatments like gene therapy hold great promise for people with haemophilia, potentially offering a way to reduce or even eliminate the need for regular injections. By carefully following patients over time, this study will provide crucial information to doctors and patients alike, helping them understand the full picture of these therapies beyond their initial effects. This information will help make sure these treatments are as safe and effective as possible for everyone.

Wichtige Erkenntnisse

  • This study follows people who have received gene therapy for haemophilia A or B.
  • The main goal is to check the long-term safety and how well the treatment keeps working.
  • Researchers will monitor for side effects like blood clots or liver problems.
  • It's for adult males who have already had one of the gene therapies.
  • Participation involves regular clinic visits for checks and blood tests.
  • The study helps us learn more about these new treatments for the future.

Wer könnte berechtigt sein?

This study is looking for participants who have already received one of the special gene therapy treatments for haemophilia A or haemophilia B. Specifically, it's for those with severe to moderately severe haemophilia B.

You must be at least 18 years old to be considered for this study. There is no upper age limit, meaning adults of any age can potentially take part.

Due to how haemophilia A and B typically affect people, only males can participate in this study.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. I am an adult (18 years or older).
  2. I am male.
  3. I have haemophilia A or severe to moderately severe haemophilia B.
  4. I have already received a single gene therapy treatment for my haemophilia.
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you join this study, you will be followed over a long period. Since you've already received the gene therapy, the study will involve regular visits to a clinic. During these visits, the study team will take blood samples to check your clotting factor levels and to look for any signs of side effects, like liver changes or blood clots. They will also ask you about your health, any bleeds you've had, and what medicines you are taking. You might also complete questionnaires about your quality of life. The exact number and frequency of visits, as well as the total duration of your participation, will be explained by the study team, but it's typically for many years to track long-term effects.

Potenzielle Risiken und Vorteile

Potential benefits of participating include contributing valuable information that helps improve our understanding of long-term gene therapy effects for haemophilia, which could help future patients. There are no new treatments given in this study, as it's observing effects of a treatment you've already had. Potential risks are generally associated with regular blood draws, which might cause some discomfort, bruising, or, rarely, infection. The study team will explain all known risks. You can choose to leave the study at any time, for any reason, without it affecting your medical care.

Standorte (6)

Einige Standortangaben sind ungefähr. Wir arbeiten daran, dies zu verbessern — bitte überprüfen Sie die Angaben mit dem Versuchsteam, bevor Sie reisen.
  • —
    Unbestätigt
    Italien
  • —
    Unbestätigt
    Deutschland
  • —
    Unbestätigt
    Frankreich
  • —
    Unbestätigt
    Spanien
  • —
    Unbestätigt
    Schweden
  • —
    Unbestätigt
    Griechenland

Häufige Fragen

What is haemophilia A or B?

Haemophilia is a condition where your blood doesn't clot properly. People with haemophilia A are missing clotting factor VIII, and people with haemophilia B are missing clotting factor IX. This can lead to longer bleeding episodes.

Was ist Gentherapie?

Gene therapy is a new type of treatment that aims to correct the genetic problem causing haemophilia. For haemophilia, it usually involves giving your body new instructions to make the missing clotting factor it needs.

Why is this study necessary if I've already had gene therapy?

This study is important because it helps scientists understand the long-term safety and effectiveness of these new gene therapies over many years, which isn't fully known yet. It helps gather vital information for future patients.

Will I receive any new treatment during this study?

No, this study does not involve giving you any new treatments or medicines. It is a follow-up study to observe the effects of the gene therapy you received in the past.

Muss ich bezahlen, um an dieser Studie teilzunehmen?

No, participation in a clinical study is usually free, and study-related medical care is covered. You won't have to pay to take part.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.